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During malignant transformation, cancer cells acquire genetic
changes through a multistep process. Maintenance of telomeres,
the very ends of chromosomes, is predicted to play the key role for
bypass of senescence – a process which can be prematurely
induced or overcome by a number of oncogenes (Serrano et al,
1997; Lin et al, 1998; Zhu et al, 1998). High levels of telomerase
activity are observed in almost all cell lines and 80–90% of human
tumours (Shay and Bacchetti, 1997). In contrast, only low levels of
telomerase activity are detected in normal tissues, mainly within
lymphocytes and physiologically regenerating epithelial cells
(Kolquist et al, 1998). The correlation between telomerase activa-
tion during cellular immortalization and activation in tumours has
led to the view that telomerase activation is required for tumour
growth. 
P16 is specified by the a transcript containing exons 1a, 2 and 3
of the INKa/ARF locus (Quelle et al, 1995). P16 inhibits the asso-
ciation between CDK4/6 and D-type cyclins, and thereby blocks
cyclin-D-directed CDK4/6 phosphorylation of pRb, prevention
exit from G1 phase (Planas-Silva and Weinberg, 1997). The role of
p16 in tumorigenesis is well established (Serrano et al, 1996). P16
knockout mice are tumour prone. P16 inactivation is seen in a
broad spectrum of human cancers, particularly those resulting
from exposure to carcinogens, including up to 80% squamous-cell
carcinomas of the head and neck epithelium (SCCHN) (Reed et al,
1996; Jares et al, 1997; Olshan et al, 1997; Papadimitrakopoulou
et al, 1997; Pande et al, 1998). Alternatively, deregulation of the
G1/S checkpoint is achieved through pRb deletion, cyclin D1 over-
expression or CDK4 mutation (Yoo et al, 1994; Barthova et al,
1995; Okami et al, 1999). Loss of p16 function may be involved in
escape from the normal limits on cellular proliferative life span
(Huschtscha and Reddel, 1999). There is evidence for the specific
inactivation of p16 upon human keratinocyte immortalization
(Munro et al, 1999). 
It has been shown in vitro that both pRb/p16INK4a inactivation
and telomerase activity are required to immortalize epithelial cells
(Kiyono et al, 1998). Human squamous-cell carcinoma (SCC)
keratinocytes immortalization requires the targeting of 4 pathways
including inactivation of p16 and another involving a repressor
of telomerase activity (Loughran et al, 1997). 14-3-3sigma-
dependent bypass of senescence in human primary keratinocytes is
accompanied by maintenance of telomerase activity and by down-
regulation of the p16 tumour suppressor gene (Dellambra et al,
2000). Significant reductions in tumour formation in vivo and
oncogenic potential in vitro are observed in late generations of
mice doubly null for the telomerase RNA(mTR) and the INK4a
tumour suppressor gene (Greenberg et al, 1999). However it is not
clear whether telomerase activation is linked to p16 inactivation in
human tumours. 
The goal of our study was to evaluate whether progression of
disease is accompanied by parallel changes in telomerase activity
and alterations of components of the pRb pathway. The underlying
hypothesis was that telomerase activation and alterations of the
cell cycle regulators cooperate during tumour progression.
Therefore, we studied telomerase activity levels as determined by
the semi-quantitative TRAP assay in parallel to p16 expression in
premalignant and malignant cells as determined by immuno-
histochemistry. Since p16 is only one player of the p16/pRb
pathway, we have also evaluated by immunohistochemistry other
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components of this pathway (i.e. pRb and cyclin D1). Moreover
and since the p16/pRb pathway can also be targeted by the E7 gene
product of oncogenic human papillomaviruses (HPV) (Jones and
Munger, 1996), we have also performed a PCR-detection of HPV
genome in our samples. 
PATIENTS AND METHODS 
Patients 
The premalignant and malignant specimens of the head and neck
epithelium were archived tissue samples of surgically biopsied
lesions from 46 patients treated at Hospital Tenon, Paris, France
between 1996 and 1998. After biopsy, about half of each specimen
had been embedded in OCT (Tissue-Tek: Miles, Elkhart, IN) and
quick frozen in liquid nitrogen. The remaining half had been fixed
in 10% buffered formalin for 24 hours or less and routinely
embedded in paraffin. Sections were made 2–3 weeks prior to
performing the immunohistochemistry. 
Cases were selected on the basis of histological criteria.
Premalignant lesions were recognized on the basis of described
criteria (Crissman and Zarbo, 1989) and classified by mutual
agreement between two observers (PF and J-CS) in the following
groups: mild, moderate and severe dysplasia. Cases for which the
histological presentation differed between paraffin-embedded and
frozen sections were excluded. All premalignant paired paraffin-
embedded and frozen specimens during the two-year period were
consecutively included. The 21 premalignant lesions were from 20
cancer-free patients. One specimen of mild dysplasia was obtained
from case 8 for whom a previous moderate dysplasia specimen
was also available (metachronous presentation). The 27 SCC
samples were from 26 randomly selected cancer patients. One
specimen of SCC came from case 2 for whom a specimen of mild
dysplasia has already been selected in the group of premalignant
lesions (metachronous presentation). 
Telomerase assay 
Frozen tissue samples, as small as 2 mm in diameter and for which
a histological control was performed, were homogenized in 100 ml
of lysis buffer (CHAPS) and incubated for 30 min at 4˚C. The
lysates were centrifuged at 16 000 g for 20 min at 4˚C and super-
natants were transferred into fresh Eppendorf tubes and stored at
–80˚C until use. Protein concentration was carefully measured
twice in each extract using the Bio-Rad Protein Assay (Bio-Rad
Laboratories, California). Telomerase activities were assessed
using the TRAPeze ELISA Telomerase detection kit (Oncor,
Gaitherburg, MD) according to manufacturer’s instructions.
Assays have been performed twice in independent experiments
using for each sample a constant amount of 0.1 mg of lysates. 
In brief, when using the TRAPeze ELISA Telomerase detection
kit (Oncor), lysates were incubated for the first steps in presence of
a biotinylated telomerase substrate oligonucleotide (b-TS) at 30˚C
for 30 min. Then, the extended products were amplified by a poly-
merase chain reaction (PCR) using Taq polymerase (Pharmacia
Biotech, Upsala, Sweden), the b-TS, RP primers and a deoxy-
nucleotide mix containing dCTP labelled with dinitrophenyl
(DNP). The PCR conditions were 33 cycles of 94˚C for 30 s and
55˚C for 30 s. After PCR, the TRAP products were tagged with
biotin and DP residues. The labelled products were immobilized
onto streptavidin-coated microtitre plates via biotin-streptavidin
interaction, and then detected by anti-DNP antibody conjugated to
horseradish peroxidase (HPR). The amount of TRAP product was
evaluated after addition of the peroxidase substrate (3,3¢,5,5¢-
tetramethylbenzidine or TMB) by measuring absorbance at
450 nm and 595 nm (Microplate Reader 3550, Bio-Rad
Laboratories). Our ELISA results were confirmed by a direct
visualization of the TRAP ladder by a 12.5% non denaturing
polyacrylamide gel electrophoresis. 
Assays have been performed twice in independent experiments
using a constant amount of 0.1 mg of lysates, for each sample that
permits obtaining DO values in the linear range of the assay (Haik
et al, 2000). Each sample was tested along with a heat inactivated
(65˚C for 10 min) or RNase-treated aliquot. Reagent controls
which lacked cell extracts were also systematically performed.
According to the manufacturer’s instruction absorbance of the
inactivated sample was to be less than 0.25 in order to consider
any result as accurate, and a sample was considered to be positive
if the increase of absorbance: Ai (i.e. Absorbance of sample –
Absorbance of inactivated sample) was over 0.15. The positive
tumours (Ai > 0.15) were then ranked in two categories depending
on the increase of absorbance. When Ai was between 0.15 and 0.5,
the sample was considered to express a low telomerase level, and
when Ai was over 0.5 the sample was defined as having a high
telomerase level. 
Immunohistochemistry: detection of p16, cyclin D1,
pRb and Ki67 
Immunohistochemical stains were performed using a mouse
monoclonal anti-p16 clone DCS-50.1/A7 (Neomarker, Union
City, CA), a mouse monoclonal anti-cyclin D1 clone DCS-6
(Neomarker, Union City, CA), a rabbit polyclonal anti-Ki 67
(Dako, Trappes, France) and a mouse monoclonal anti-pRb clone
G3-245 (Pharmingen, Los Angeles, CA). Deparaffinized sections
were microwaved at 600 Watts 3 times for 5 min in 250 ml of
0.01 M sodium citrate buffer pH 6.0, and allowed to cool at room
temperature for 20 min. The following steps were performed in an
automated immunohistochemical processor (Ventana, Tucson,
Arizona). Primary antibodies were incubated at 37˚C for 30 min
(p16, pRb, Ki67: dilution 1:200; cyclin D1: dilution 1:150). For
detection of all 4 bound antibodies, we used the Enhanced DAB
Detection kit (Ventana, Tucson, Arizona). Slides were finally
counterstained with Harris haematoxylin, and mounted. Normal
epithelial tissue samples from the tonsil were used as an external
positive control for the 4 antibodies, and were also stained with
omission of the primary antibody in order to confirm staining-
specificity. In addition the F9605 cell line was used as a negative
external control for p16 (Gruis et al, 1995). Non-neoplastic
stromal cells served as internal positive controls for pRb and p16
in each biopsy sample. 
Specimens were blindly evaluated by a pathologist (PF) and
another investigator (J-CS). Nuclear staining was used to identify
positive cells. Representative areas of each tissue section were
selected, and cells were counted in at least 4 fields (at 3 400) in
these areas. In each field at least 200 tumour cells were evaluated
for each stain. Intensity of positive staining was graded as
minimal, moderate, and strong. Absolute percentage of positive
cells were recorded. Cases with a difference of more than 10%
between observers were reviewed. Finally, average percentage
was taken for each stain. HPV detection 
HPV detection was performed by means of PCR using E6-directed
consensus primers and 32P-kinased type-specific oligonucleotide
probes for types 16, 18, 31 and 33 as described elsewhere (Resnick
et al, 1990). For each sample, 4 sections of 10 mm were used for
HPV detection. Negative control samples and positive control
samples from the uterine cervix known to contain various types
were included in each amplification. PCR products from positive
samples were also used to provide a control for each hybridization. 
Statistical analysis 
Cases were classified as positive for telomerase activity if they
demonstrated telomerase activity levels above the 0.15 level, as
stated by the manufacturer. A complete absence of p16 or pRb
staining was required to identify negative cases. Overexpression
of cyclin D1 or Ki67 was determined using the median of the
percentage of positive cells as a cut-off. 
To evaluate trends in the percentage of positive cases for each
variable as defined above with regard to severity of disease, lesion
types were ordered according to their severity as mild dysplasia,
advanced (moderate or severe) dysplasia and carcinoma, and
assigned a score of 0, 1, and 2 respectively. Trends in proportions
were identified using the Mann-Whitney U test, which is based on
ranks and is applicable to very small samples (Moses et al, 1984). 
All analyses were carried out with StatView software version
4.02. A level of 0.05 was chosen to indicate statistical signifi-
cance. All reported P values are two-sided. 
RESULTS 
Telomerase activity 
Telomerase-positive samples showed the characteristic processive
6-bp ladder upon PAGE (Figure 1). RNAse treatment or heat
inactivation of cell extracts completely eliminated the signal
demonstrating the specificity of the enzymatic detection. 
The results of the TRAPeze ELISA Telomerase detection assay
are shown in Table 1. Of a total of 48 samples 43 (90%) exhibited
telomerase activity. High (>0.5) levels of telomerase activity were
observed in 37 samples (77%). 
Immunohistochemistry of p16, cyclin D1, pRb and Ki67
proteins 
The results of immunohistochemical analysis of p16, pRb, Ki67
and cyclin D1 expression are summarized in Table 1. Figure 2
shows examples of immunohistochemical staining for p16 (A and
B), cyclin D1 (C and D), pRb (E) and Ki67 (F). Strong nuclear
staining for p16 was sometimes associated with a weak to
moderate cytoplasmic staining. Specificity of the immuno-
reactivity was confirmed by negative and internal or external
positive controls for each antibody (see mesenchymal cells
positive for p16 in Figure 2A and B) as described in methods. 
34 of 48 (71%) lesions were totally unreactive with the p16 anti-
body. Lesions with p16 expression showed considerable hetero-
geneity in the proportion of positive cells (2 to 99%). All cases
regarded as p16-negative had at least a few positive stromal 
cells as an internal positive control, therefore, validating p16 
staining. 
In contrast to p16 which was frequently negative, all lesions but
one (98%) showed pRb immunoreactivity. The pRb staining was
strong in all positive samples, although the proportion of positive
cells extended from 3 to 95%. 
All samples were strongly positive for Ki67. The median of the
percentage of positive cells was 41.25% (range 13.5 to 80%). 
43 (90%) of 48 samples were immunoreactive with the cyclin
D1 antibody. The median of the percentage of positive cells was
27% (range 0–66.5%). There was some heterogeneity of intensity
of staining, which was strong in 17 cases (35%), moderate in 14
cases (29%), and weak in 12 cases (35%). 
HPV status 
This study identified HPV in 4 of 48 tested samples (8.3%)
(Table 1). Among these HPV-positive samples, there was one mild
dysplasia, one advanced dysplasia and two SCC. Three cases were
positive for the high-risk HPV type 16, while the remaining case
was positive for HPV type 31. Interestingly, among premalignant
lesions, the sample (case 3, mild dysplasia) demonstrating the
highest telomerase activity was HPV-positive for type 16, and the
sample (case 14, advanced dysplasia) exhibiting the highest
percentage of p16 positive cells (97.5%) was also HPV-positive. 
Telomerase activity, p16, cyclin D1 and Ki67 status
according to severity of lesions 
Proportions of cases demonstrating high levels of telomerase
activity, expressing p16 or overexpressing cyclin D1 or Ki67
according to lesion types are shown in Figure 3.
Of 9 mild dysplasia, 5 (55%) demonstrated telomerase activity,
and in 4 (44%) levels of telomerase activity were high (>0.5). 12
of 12 (100%) advanced dysplasia and 26 of 26 (100%) SCC ex-
hibited telomerase activity, and the activity levels were high in 8 of
506 JC Soria et al
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Figure 1 Detection of telomerase activity in cell extracts from premalignant
and malignant lesions. Polyacrylamide gel electrophoresis separation of
telomerase ladder. Lanes 1 and 2: patient no. 2 (light dysplasia and
squamous-cell carcinoma); lanes 3 and 4: patient no. 8 (light dysplasia and
moderate dysplasia); lane 5: patient no. 24; lane 6: patient no. 43; lane 7:
positive control; lane 8: lysis buffer; lanes 9 to 14: respective RNase-
inactivated controls; lanes MW: molecular weight marker Telomerase activity and p16 status in the head and neck epithelium 507
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12 (67%) advanced dysplasia and all but two (92%) SCC. The
trend of increasing proportions of cases demonstrating high levels
of telomerase activity with severity of lesions was significant (P =
0.009). 
Mild or moderate staining for cyclin D1 in suprabasal cells was
characteristic of mild dysplasia (Figure 2C), while strong staining
was observed in a majority of tumour cells in SCC (Figure 2D).
The trend of increasing proportions of cases overexpressing cyclin
D1 (above the median) with severity of lesions was significant
(P = 0.02) as 2 of 9 mild dysplasia (22%), 4 of 12 (33%) advanced
dysplasia, and 18 of 27 (66%) SCC samples overexpressed cyclin
D1. Analysis of cyclin D1 staining intensity also showed that
strong staining was observed in none of 9 (0%) mild dysplasia, in
4 of 12 (25%) advanced dysplasia, and 13 of 27 (48%) SCC 
(P = 0.01). 
In contrast to staining with cyclin D1, most SCC were p16 nega-
tive (Figure 2B). An inverse trend of decreasing proportions of
cases expressing p16 with severity of lesions was observed (P =
0.01). 6 of 9 (67%) mild dysplasia displayed p16 expression with a
wide range from 3.5 to 59% positive epithelial cells, as well as 4 of
12 (33%) advanced dysplasia (Figure 2A). Only 4 of 27 (15%)
SCC were p16-positive, although the proportion of positive
tumour cells could reach 99% in these cases. 
Overexpression of Ki67 was found in 3 of 9 mild dysplasia
(33%), 4 of 12 advanced dysplasia (33%) and 17 of 27 SCC (63%;
Figure 2F), but this trend was not significant (P = 0.08). 
Table 1 Summary of patient characteristics, lesion type, immunohistochemistry of p16, cyclin D1, Ki 67, and pRb proteins, HPV typing, and telomerase activity
assay in 21 premalignant and 27 malignant lesions of the head and neck
Patient no. Age Sex Lesion type Telomerase (intensity) P16 Cyclin D1 Ki67 Rb HPV type 
1 59 M Mild dysplasia High Retained Overexpressed High Retained Negative 
2a 63 M Mild dysplasia Negative Lost Low Low Retained Negative 
3 79 F Mild dysplasia High Retained Overexpressed Low Retained 16 
4 67 M Mild dysplasia High Retained Low High Retained Negative 
5 58 M Mild dysplasia Low Retained Low High Retained Negative 
6 63 M Mild dysplasia Negative Retained Low Low Retained Negative 
7 55 M Mild dysplasia Negative Retained Low Low Retained Negative 
8b 58 M Mild dysplasia Negative Lost Low Low Retained Negative 
9 52 F Mild dysplasia High Lost Low Low Retained Negative 
10 51 M Moderate dysplasia Low Lost Low Low Retained Negative 
11 50 F Moderate dysplasia High Retained Low Low Retained Negative 
12 57 M Moderate dysplasia High Lost Low High Retained Negative 
13 71 M Moderate dysplasia Low Lost Low Low Retained Negative 
14 59 M Moderate dysplasia High Retained Low High Retained 16 
15 61 M Moderate dysplasia Low Lost Low Low Retained Negative 
8a 56 M Moderate dysplasia High Lost Low Low Retained Negative 
16 47 M Severe dysplasia High Retained Overexpressed Low Retained Negative 
17 84 M Severe dysplasia High Lost Overexpressed Low Retained Negative 
18 42 M Severe dysplasia High Lost Overexpressed High Retained Negative 
19 50 M Severe dysplasia High Lost Low Low Retained Negative 
20 46 M Severe dysplasia Low Retained  Low High Retained Negative 
21 37 M Carcinoma High Lost Low High Retained Negative 
22 41 F Carcinoma High Retained Low Low Retained Negative 
23 72 F Carcinoma High Retained Low High Retained Negative 
24 72 M Carcinoma High Lost Overexpressed Low Retained 16 
25 46 M Carcinoma High Lost Overexpressed High Retained Negative 
26 49 M Carcinoma High Lost Overexpressed High Retained Negative 
27 57 M Carcinoma High Lost Low Low Retained Negative 
28 45 M Carcinoma Low Lost Overexpressed Low Retained Negative 
29 45 M Carcinoma High Lost Low Low Retained Negative 
30 60 M Carcinoma High Lost Overexpressed High Retained Negative 
31 63 F Carcinoma High Lost Low High Retained Negative 
32 62 M Carcinoma Low Lost Overexpressed High Retained Negative 
33 62 F Carcinoma High Lost Overexpressed High Retained Negative 
34 51 M Carcinoma High Lost Low Low Retained Negative 
35 44 M Carcinoma High Lost Overexpressed High Retained Negative 
2b 63 M Carcinoma High Lost Overexpressed Low Retained Negative 
36 67 M Carcinoma High Lost Low High Retained Negative 
37 48 M Carcinoma High Lost Overexpressed High Retained Negative 
38 49 F Carcinoma High Lost Overexpressed High Retained Negative 
39 62 M Carcinoma High Lost Overexpressed High Retained Negative 
40 49 M Carcinoma High Retained Overexpressed Low Retained Negative 
41 68 F Carcinoma High Lost Overexpressed Low Retained Negative 
42 59 M Carcinoma High Retained Overexpressed High Retained Negative 
43 75 M Carcinoma High Lost Overexpressed Low Retained Negative 
44 58 M Carcinoma High Lost Overexpressed High Lost Negative 
45 54 M Carcinoma High Lost Low High Retained 31 
46 70 F Carcinoma High Lost Overexpressed High Retained Negative 
Patients 2 and 8 are shown twice as they presented consecutively with different lesions (metachronous presentation). 508 JC Soria et al
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DISCUSSION 
A majority of SCCHN are known to demonstrate high telomerase
activity, inactivation of p16, and/or overexpression of cyclin D1
(Reed et al, 1996; Jares et al, 1997; Olshan et al, 1997). Moreover,
high telomerase activity (Mao et al, 1996; Mutirangura et al,
1996), or inactivation of p16 (Papadimitrakopoulou et al, 1997;
Pande et al, 1998), or overexpression of cyclin D1 (Izzo et al,
1998) have been observed separately in a proportion of premalig-
nant lesions of the head and neck epithelium demonstrating that
these abnormalities may occur at the preinvasive stage of disease.
Our results are clearly consistent with these observations. Our
study is the first one to show in the same set of samples of pre-
malignant and malignant lesions the parallel occurrence of the
most frequently encountered oncogenic changes involving cell




Figure 2 Examples of immunoreactivity with the p16 (A–B), cyclin D1 (C–D), pRb (E) and Ki67 (F) antibodies. (A) Focal positivity for p16 in a case of
advanced dysplasia (patient no. 16), (B) complete lack of p16 reactivity in tumour cells in a case of squamous-cell carcinoma (patient no. 26), (C) suprabasal
expression of cyclin D1 in a case of mild dysplasia/keratosis (patient no. 4), (D) strong and diffuse staining for cyclin D1 in a case of squamous-cell carcinoma
(patient no. 32), (E) a dysplasia showing a strong positive reaction in the nuclei of cells for pRb (patient no. 18), (F) a squamous-cell carcinoma with most
carcinoma cells positive for Ki-67 (patient no. 45) Telomerase activity and p16 status in the head and neck epithelium 509
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activation. Telomerase activation and p16 disruption are both
required for the immortalisation process of epithelial cells in vitro
models (Kiyono et al, 1998). Here in an in vivo study, we demon-
strate that the tumorigenic progression in the head and neck
epithelium is clearly associated with telomerase activation along
with p16 inactivation. 
Our findings were established in cases carefully selected to
display identical histological presentation in contiguous frozen and
paraffin-embedded parts. The antibodies for pRb and p16 were
chosen among other commercially available reagents because there
were previous studies in the literature showing a good concordance
between immunoreactivity with these reagents in tissue sections and
the results of parallel genetic analysis (Geradts et al, 1994; Bartkova
et al, 1995; Reed et al, 1996). These studies have concluded to the
value of using immunohistochemistry for assessing small lesions for
which sufficient DNA is not available for detailed genetic analysis.
Moreover, the F9605 cell line which is homozygously deleted at the
INK4a locus (Gruis et al, 1995) was assayed as an external negative
control for the p16 antibody. An advantage of the DCS 50.1 anti-
body over other antibodies for p16 is that sample negativity is
unambiguously defined by the complete absence of positive cells.
Epitope masking or lability can be important problems in paraffin-
embedded sections, however. The frequency of p16-negative SCC
in our series (85%) was very close to the previously reported
frequency (83%) in the series of Reed et al, which was performed on
frozen specimens and showed a good concordance between
immunoreactivity and genetic lesions. We avoided overfixation by
limiting the length of time in fixative to less than 24 hours for all
cases. Sections were made 2–3 weeks prior to performing the
immunostaining. Importantly, there was a positive internal control
for pRb or p16 in each case, which clearly demonstrates that these
epitopes were detectable in tissue sections even though tumour cells
were negative. Wu et al also found a high frequency, (87%) of p16
loss in a series of oral and oropharyngeal carcinomas and concluded
that DNA studies may underestimate the true prevalence of p16 loss
(Wu et al, 1999). Overexpression of cyclin D1 in specimens
analysed by immunohistochemistry also indicates that
DNA analysis may underestimate the frequency of cyclin D1
abnormalities (Bartkova et al, 1995). On the other hand, missense
mutations of p16 may well stain using immunohistochemistry
(Zhang et al, 1994; Munro et al, 1999), although the rate of point
mutations of p16 is generally low in SCCHN (Zhang et al, 1994;
Reed et al, 1996; Gazzeri et al, 1998; Sanchez-Cespedes et al, 1999).
Tumour 44, which had no p16 and no pRb, is an intriguing case. Im-
munostaining for p16 or pRb was clearly positive with nuclear
staining on many stromal cells. Tumour cells were completely
unstained by pRb antibody. However, they contained a moderate to
strong amount of cytoplasmic p16 without concomitant nuclear
staining. This case was thus considered to be p16-negative. It is true
that p16 and pRb mutations are almost always mutually exclusive
(Kinoshita et al, 1996; Kratzke et al, 1996). However, a few tumours
have been described with p16 and pRb alterations suggesting that
either one of these genetic changes may lead to an additional growth
advantage for the transformed cell (Sanchez-Cespedes et al, 1999).
The INK4a locus harbours both p16 and p14/ARF genes (Quelle
et al, 1995). Specific inactivation of the p16/pRb pathway relates to
evasion of senescence, while p14/ARF regulates the p53 pathway
(Munro et al, 1999). It is conceivable that the pRb pathway may be
disabled through loss of pRb, while alteration at the INK4a locus
represents an additional oncogenic event targeting the p53 pathway.
Exclusive cytoplasmic p16 staining has been related to a more
aggressive behaviour in breast cancer (Emig et al, 1998). Case 44
was a poorly differentiated SCCHN with a high mitotic count and a
high percentage of Ki67 positive cells. However, we could not docu-
ment the follow-up in this case. 
We analysed the telomerase activity of our samples using the
TRAP method (Shay and Bacchetti, 1997). Unfortunately this
technique does not allow an in situ analysis of telomerase activity,
and the precise contribution of infiltrating lymphocytes is hard to
ascertain regarding positive results. To our knowledge, there is no
method fully reliable to directly evaluate telomerase activity at the
cellular level. We have tried, as others, some commercially avail-
able antibodies against TERT, but without satisfactory results
(Dhaene et al, 2000). In situ hybridization of TERT – the catalytic
subunit of telomerase which is assumed to be directly responsible
for activation of telomerase – might be an alternative while
waiting for suitable anti-hTERT antibodies (Kolquist et al, 1998).
However, even with this technique some authors were unable to
find a strict correlation between telomerase activity and hTERT
mRNA expression (Nakano et al, 1998). For these reasons, we
analysed the telomerase activity of our samples using the TRAP
method. Although the telomerase activity levels cannot be consid-
ered as quantitative due to the exponential nature of the PCR
amplification, we and others (Sumida et al, 1999; Haik et al, 2000)
have consistently shown that differences in telomerase activity
levels can be shown reproducibly using the TRAP assay.
Therefore we felt entitled to split telomerase-positive lesions in
two groups of high and low level of expression depending on the
increase of absorbance. The cut-off point of 0.5 in the increase of
absorbance (Absorbance of sample – Absorbance of inactivated
sample) is somewhat arbitrary, but it was the one reflecting the
best visual evaluation of the TRAP-ELISA result (weak or strong
colour reaction). As previously stated, since the TRAP assay is
performed on a homogenate it is difficult to interpret our findings
at the cellular level. However our results, when analysed in rela-
tion to histological changes, clearly show that the proportions of
cases demonstrating high telomerase activity increase in a con-
tinuous manner with phenotypic progression from the earliest
















Figure 3 Proportions of cases demonstrating high levels of telomerase
activity, expressing p16 or overexpressing cyclin D1 or Ki67 according to
lesion types. The trends in proportions were found significant for telomerase
activity (P = 0.009), overexpression of cyclin D1 (P = 0.02) and expression
p16 (P = 0.01) 510 JC Soria et al
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dysplasia) to advanced premalignant lesions (moderate or severe
dysplasia) and to subsequent invasive carcinoma (Figure 3). An
increased telomerase activity with increasing head and neck cancer
stage has been reported before (Mao et al, 1996; Mutirangura et al,
1996), and is reminiscent of TERT expression in human breast and
colon tissues where it begins with early pre-invasive changes and
increases gradually during tumour progression (Kolquist et al,
1998). This suggests a continuous selection of cells with higher
telomerase activity during tumour progression in contrast to the
late and stochastic activation by cells in culture. Of special interest
are the two cases with metachronous presentation (cases 2 and 8).
Indeed a transition from TRAP-negative to -positive results is
observed in the biopsies. However the precise meaning of this
observation remains elusive since it could either represent
different stages in the development of the same tumour cell
population or could be simply related to independent lesions. 
The coincident loss of p16 and telomerase activation during
tumour progression strongly suggests these events cooperate in
conferring immortality to tumour cells. Telomerase activation and
p16 disruption are required to immortalize epithelial cells (Kiyono
et al, 1998). Keratinocyte immortalization can be achieved without
affecting other major growth control or differentiation systems
(Dickson et al, 2000), which is perfectly consistent in our study
with the observation of telomerase activation and p16 loss in a
low percentage of early lesions (keratoses/light dysplasia), which
are defined by minimal disturbance of tissular differentiation
and slight degree of atypia. However, cultures from different
stages of SCCHN have revealed that immortality is a frequent, but
dispensable event at a late stage during tumour progression
(Edington et al, 1995). In addition to p16 loss and telomerase acti-
vation two pathways are involved to immortalize human SCC
keratinocytes, which may explain why more carcinomas appear to
be p162/2  and telomerase-positive than there are immortal
SCCHN (Loughran et al, 1997). To prove that the coincident loss
of p16 and telomerase activation in our cases do actually result in
immortalization of tumour cells as expected would have required
to relate this molecular profile to the appearance of immortal
variants in cultures. 
HPV infection affected less than 10% of our cases. The interfer-
ence of HPV on telomerase activity or the pRb pathway is well
demonstrated by experimental studies (Jones and Munger, 1996;
Klingelhutz et al, 1996). We do not provide evidence that HPV is
functionally significant since we do not demonstrate that there
is at least one copy of the virus per cell, but our observations are
consistent with experimental data. 
In conclusion, our study shows that telomerase activation and
the most commonly observed oncogenic changes involving cell
cycle regulators accumulate continuously with disease progression
in the head and neck tumorigenic process. A better evaluation
of the relationships between these variables at the cellular level
might provide additional information regarding the chronological
organization of these events. 
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